These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30365357)

  • 1. Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.
    Gantois I; Popic J; Khoutorsky A; Sonenberg N
    Annu Rev Med; 2019 Jan; 70():167-181. PubMed ID: 30365357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early metformin treatment: An effective approach for targeting fragile X syndrome pathophysiology.
    Choi JH; Marsal-García L; Peraldi E; Walters C; Huang Z; Gantois I; Sonenberg N
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2407546121. PubMed ID: 39042682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational endpoints in fragile X syndrome.
    de Esch CE; Zeidler S; Willemsen R
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():256-69. PubMed ID: 24184744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward fulfilling the promise of molecular medicine in fragile X syndrome.
    Krueger DD; Bear MF
    Annu Rev Med; 2011; 62():411-29. PubMed ID: 21090964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
    Gantois I; Khoutorsky A; Popic J; Aguilar-Valles A; Freemantle E; Cao R; Sharma V; Pooters T; Nagpal A; Skalecka A; Truong VT; Wiebe S; Groves IA; Jafarnejad SM; Chapat C; McCullagh EA; Gamache K; Nader K; Lacaille JC; Gkogkas CG; Sonenberg N
    Nat Med; 2017 Jun; 23(6):674-677. PubMed ID: 28504725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
    Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
    Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
    Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated ERK/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice.
    Sawicka K; Pyronneau A; Chao M; Bennett MV; Zukin RS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(41):E6290-E6297. PubMed ID: 27663742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model.
    Gross C; Banerjee A; Tiwari D; Longo F; White AR; Allen AG; Schroeder-Carter LM; Krzeski JC; Elsayed NA; Puckett R; Klann E; Rivero RA; Gourley SL; Bassell GJ
    Neuropsychopharmacology; 2019 Jan; 44(2):324-333. PubMed ID: 30061744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model.
    Takeda R; Ishii R; Parvin S; Shiozawa A; Nogi T; Sasaki Y
    Neurosci Lett; 2023 Jul; 810():137317. PubMed ID: 37286070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.
    Santos AR; Kanellopoulos AK; Bagni C
    Learn Mem; 2014 Oct; 21(10):543-55. PubMed ID: 25227249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragile X syndrome: a review of clinical and molecular diagnoses.
    Ciaccio C; Fontana L; Milani D; Tabano S; Miozzo M; Esposito S
    Ital J Pediatr; 2017 Apr; 43(1):39. PubMed ID: 28420439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. microRNAs and Fragile X Syndrome.
    Lin SL
    Adv Exp Med Biol; 2015; 888():107-21. PubMed ID: 26663181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.
    Jacquemont S; Pacini L; Jønch AE; Cencelli G; Rozenberg I; He Y; D'Andrea L; Pedini G; Eldeeb M; Willemsen R; Gasparini F; Tassone F; Hagerman R; Gomez-Mancilla B; Bagni C
    Hum Mol Genet; 2018 Jun; 27(12):2039-2051. PubMed ID: 29590342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics.
    Bagni C; Tassone F; Neri G; Hagerman R
    J Clin Invest; 2012 Dec; 122(12):4314-22. PubMed ID: 23202739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragile X syndrome: from targets to treatments.
    Wijetunge LS; Chattarji S; Wyllie DJ; Kind PC
    Neuropharmacology; 2013 May; 68():83-96. PubMed ID: 23257237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
    Hoeffer CA; Sanchez E; Hagerman RJ; Mu Y; Nguyen DV; Wong H; Whelan AM; Zukin RS; Klann E; Tassone F
    Genes Brain Behav; 2012 Apr; 11(3):332-41. PubMed ID: 22268788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention.
    Bhogal B; Jongens TA
    Dis Model Mech; 2010; 3(11-12):693-700. PubMed ID: 20682752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in insulin-like growth factor signaling alter phenotypes in Fragile X Mice.
    Wise TL
    Genes Brain Behav; 2017 Feb; 16(2):241-249. PubMed ID: 27643697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.